Healthcare
Live Price
Offline$26.08
-0.87% today
1Y Change
+25.44%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Progyny, Inc. (PGNY) is a Healthcare stock with a market cap of $1.52B and listed on NASDAQ. The stock last traded around $26.08 and up 25.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +10.4%, EPS growth of +15.3%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +15.3%, free cash flow +10.4% with operating margin 6.6% and ROIC 9.6%. Valuation is more restrained than many high-expectation growth names at P/E 27.1 and price/sales 1.2. Stock Foundry combines PGNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PGNY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PGNY Max Drawdown
-42.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PGNY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$500.6M
-36.4% YoY
FY Net Income
$65.8M
+116.6% YoY
Free Cash Flow
$23.9M
-69.0% YoY
Revenue Growth
+10.4%
EPS Growth
+15.3%
Gross Margin
23.6%
Net Margin
4.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.1B | 787M | 501M |
| Gross Profit | 304M | 253M | 239M | 167M | 112M |
| Operating Income | 85M | 67M | 62M | 23M | 32M |
| EBITDA | 100M | 71M | 64M | 25M | 34M |
| Net Income | 59M | 54M | 62M | 30M | 66M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112M | 162M | 97M | 120M | 91M |
| Total Assets | 742M | 607M | 757M | 543M | 358M |
| Total Liabilities | 226M | 185M | 203M | 166M | 106M |
| Shareholder Equity | 516M | 422M | 553M | 377M | 252M |
| Total Debt | 24M | 19M | 19M | 8M | 9M |
| Net Debt | -88M | -143M | -78M | -112M | -83M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
-67.6% YoY
Capital Expenditures
2M
+34.3% YoY
Free Cash Flow
24M
-69.0% YoY
Key ratios
Gross Margin
23.6%
Operating Margin
6.6%
Net Margin
4.5%
ROE
11.4%
Debt / Equity
0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.